Daniel Rader

Has grant

Chair

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Toward molecular understanding of novel genes and pathways linking lipid metabolism and cardiovascular diseases

Open Date: 2024-01-01

Close Date: 2028-12-31

Articles (24)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

The Genome Informed Risk Assessment (GIRA) report from eMERGE has become a standard approach to implement genomic precision medicine at scale. Here, we assess GIRA's utility and impact in a health care system independent of eMERGE, focusing on 9 adult conditions using the Penn Medicine Biobank (PMBB, n=48,279). We find a large number of patients - 50.1% (n=24,185) - were deemed by GIRA as high-risk for at least one of the 9 conditions with 30.4% (n=14,676) due to polygenic and/or monogenic risk. Stratifying by ancestry revealed significant differences in high-risk proportions, with higher rates in African/African American (AFR) (56.6% vs. 50.1%, p=7.43x10-36) and lower rates in East (42.0%) and South Asian (40.0%). Increased high-risk rates were observed in the lowest quartile of social deprivation index, highlighting the influence of environmental factors and access to care on GIRA's utility. GIRA was a good predictor of prevalent cases (in-line with the eMERGE GIRA reported results); incident case prediction was substantially attenuated for 5 of the 9 conditions (e.g., OR of 2.36 vs. HR of 1.31 for atrial fibrillation (AFIB)). We find demographic compositions of high-risk patients differed from the incident cases for some of the conditions; for example, high-risk for AFIB individuals where enriched for European ancestries in contrast with incident AFIB cases that were enriched for AFR ancestries. Overall, our results show the accuracy of GIRA as a biomarker to stratify high-risk patients for precision medicine and highlight implementation challenges in its impact on the health system if implemented at scale.

Year:

2026

We built and evaluated a zero-shot LLM pipeline with automated, task-aware prompt optimization to extract radiology and symptom fields for gallstone phenotyping from de-identified EHR text. Across symptomatic, asymptomatic, and control cohorts, it performed reliably on high-signal binary fields and symptom flags but lagged on fine-grained stone burden and complications, establishing a practical baseline and motivating targeted refinements

Year:

2026

Year:

2025

Aims The distribution of abdominal adipose depots and their mechanistic links to type 2 diabetes remain incompletely understood. This study elucidated the relationship between type 2 diabetes presence and quantitative abdominal imaging traits, including hepatic steatosis, liver and spleen size, and adipose distribution, using unenhanced computed tomography (CT) scans from a large-scale, racially diverse, disease-focused medical biobank. Materials and Methods Deep learning algorithms were applied to abdominal CT scans to automatically quantify image-derived phenotypes, including spleen-hepatic attenuation difference (SHAD) for hepatic steatosis, liver and spleen volumes (LV and SV, respectively), visceral and subcutaneous adipose tissue (VAT and SAT, respectively), and visceral-to-subcutaneous fat ratio (VSR). Results Diabetic individuals demonstrated a greater degree of hepatic steatosis and central adiposity than those without diabetes. Liver attenuation was lower (47.6 vs. 52.4 Hounsfield units (HU); lower values indicate greater steatosis), SHAD was higher (−5.41 vs. −8.41 HU; more positive values indicate greater steatosis), and steatosis prevalence increased (38.4% vs. 21.4%) (all p<2.2×10⁻¹⁶). VSR was also elevated (0.64 vs. 0.54, p=5.86×10⁻¹³). These trends remained significant after stratification by sex. Multivariate analyses revealed independent associations of diabetes with SHAD (OR 1.04), LV (OR 1.59), SV (OR 3.95), VAT (OR 1.23), SAT (OR 1.05), and VSR (OR 2.27), after adjusting for age, sex, race, and BMI. Conclusions Hepatic steatosis, hepatomegaly, and visceral adiposity on CT imaging are predictive of type 2 diabetes presence. Notably, VSR showed a stronger association with diabetes than BMI, underscoring how body-fat distribution, rather than overall adiposity, more accurately reflects metabolic disease risk.

Year:

2025

Genome-wide association studies (GWAS) have identified nearly 100 loci associated with metabolic dysfunction-associated steatotic liver disease (MASLD), but the molecular functions of these variant alleles remain elusive, particularly when they occur in non-coding regions. Here we profiled the chromatin accessibility landscape of liver nuclei from MASLD individuals, and demonstrated these accessible genomic sites were bound by cell type-specific transcription factors (TFs) and enriched for MASLD risk variants, highlighting lineage- and disease state-specific regulation. Using a massively parallel reporter assay (MPRA), we identified hundreds of differential activity variants (DAVs) that operate in a cell type-specific manner or in a stimulus-dependent context by disrupting liver pathogenesis-associated transcriptional regulatory network. Integrative analyses combining liver eQTLs, chromatin looping, and single-cell CRISPRi screening linked these DAVs to functional target genes. Notably, we demonstrated that DAVs located near SLC22A3 and core regulators of triglyceride metabolism ( APOA5 , ANGPTL3 , and LPL ) loci modulate their gene expression and contribute to altered lipid metabolism and hepatic stellate cell activation. Furthermore, these DAVs exhibit predictive power in distinguishing MASLD disease risk. Together, these multimodal integration analyses provide insights into the regulatory mechanisms of MASLD progression driven by noncoding genetic risks.

Year:

2025

Genome-wide association studies (GWAS) have identified thousands of loci associated with a variety of common, complex human traits. Recent efforts have focused on characterizing chromatin accessibility to discover regulatory elements that modify the expression of nearby genes, suggesting that trait associations are mediated through changes in gene regulation. Genetic variants associated with differences in chromatin accessibility, known as chromatin accessibility quantitative trait loci (caQTLs), are established contributors to gene expression differences, providing mechanistic hypotheses for signals identified by GWAS. Using the assay for transposase-accessible chromatin with sequencing (ATAC-seq), we assessed chromatin accessibility in 189 diverse human liver samples, identifying over two million accessible chromatin regions enriched for gene regulatory features and, in 175 of these samples, over 14,000 caQTLs. Focusing subsequently on liver-relevant complex traits, we obtained publicly available blood lipids GWAS data and identified 157 loci where caQTLs, expression quantitative trait loci (eQTLs), and GWAS signals colocalized. This generated specific molecular hypotheses about regulatory elements, affected genes, and, in some cases, implicated transcription factors. Finally, we enumerated the set of blood lipid trait signals that lack an obvious proposed mechanism beyond catalogs of liver caQTLs and eQTLs. After integrating 10 multi-omic QTL regulatory mechanism datasets whilst considering limitations in statistical power, we found that approximately 20% of blood lipid GWAS signals lacked a statistical link to a proposed mechanism. Our results demonstrate the value of integrating multiple genomic datasets to improve understanding of GWAS signals, while emphasizing the need for additional experimental approaches to fully characterize complex trait associations.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (23)

Walter R. Witschey

Associate Professor

University of Pennsylvania

UNITED STATES
View details

James Gee

Professor

University of Pennsylvania

UNITED STATES
View details

Struan Grant

Professor of Genetics and Pediatrics

University of Pennsylvania

UNITED STATES
View details

Sarah Abramowitz

Stanford University

UNITED STATES
View details

Xiao Wang

University of Pennsylvania

UNITED STATES
View details

Scott M Damrauer

Assistant Professor

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Sy Hwang

University of Pennsylvania

UNITED STATES
View details

Mitchell A Lazar

University of Pennsylvania

UNITED STATES
View details

Kei Sakamoto

Professor at University of Copenhagen

University of Copenhagen

DENMARK
View details

Danielle Mowery

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Marijana Vujkovic

Research Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Benjamin F. Voight

Professor

University of Pennsylvania

UNITED STATES
View details

Michael Levin

Cardiologist

Corporal Michael J. Crescenz VA Medical Center

UNITED STATES
View details

Kate Townsend Creasy

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Wenli Yang

Research Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Rinad S. Beidas

University of Pennsylvania

UNITED STATES
View details

Kiran Musunuru

Professor

University of Pennsylvania

UNITED STATES
View details

Hersh Sagreiya

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Daniel P Kelly

Director

University of Pennsylvania

UNITED STATES
View details

Won Dong Lee

Assistant Professor

Yonsei University

SOUTH KOREA
View details

Kyong-Mi Chang

Professor of Medicine & Associate Chief of Staff for R&D

University of Pennsylvania

UNITED STATES
View details

Dipsikha Biswas

Københavns Universitet

DENMARK
View details

David Kaplan

Associate Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details